Recent Patents on Anti-Cancer Drug Discovery This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

TENT5A Increases Glioma Malignancy and Promotes its Progression
CONCLUSION: Our data showed that the expression of TENT5A is associated with the pathological grade of glioma. Knockdown of TENT5A decreased the ability of proliferation, invasion and migration of glioma cells. High levels of TENT5A in glioma cells are lethal. Therefore, TENT5A could be a new target for glioma treatment.PMID:38204269 | DOI:10.2174/0115748928280901231206102637 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 11, 2024 Category: Cancer & Oncology Authors: Jiali Hu Lei Zeng Ronghuan Hu Dan Gong Mengmeng Liu Jianwu Ding Source Type: research

Exosome-Derived Cargos in Immune Microenvironment in Esophageal Carcinoma: A Mini-Review
Recent Pat Anticancer Drug Discov. 2024 Jan 3. doi: 10.2174/0115748928280161231123060159. Online ahead of print.ABSTRACTEsophageal carcinoma, a lethal malignancy with limited treatment options and poor prognosis, necessitates understanding its underlying mechanisms and identifying novel therapeutic targets. Recent studies have highlighted the critical role of the immune microenvironment in esophageal carcinoma, particularly the interplay between tumor cells and immune cells mediated by exosomes and their cargos. Exosomes, small extracellular vesicles secreted by various cells, including tumor cells, facilitate intercellula...
Source: Recent Patents on Anti-Cancer Drug Discovery - January 4, 2024 Category: Cancer & Oncology Authors: Yakun Zhang Xiaoyan Sun Yan Guan Ying Sun Source Type: research

Optimal Rituximab Monotherapy in Splenic Marginal Zone Lymphoma (SMZL): A Case Report and Brief Review
CONCLUSION: Our analysis found no statistically significant difference between rituximab monotherapy and rituximab combined with chemotherapy, while rituximab treatments resulted in better therapeutic effects than chemotherapy. Rituximab monotherapy has favorable therapeutic effects and minor adverse effects (AEs) in treating SMZL.PMID:37937574 | DOI:10.2174/0115748928247369231024112003 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 8, 2023 Category: Cancer & Oncology Authors: Rong-Yan Guan Xing-Ru Tang Zou-Fang Huang Jun Du Xue-Hang Fu Guang Lu Wei-Wei Mou Source Type: research